Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Optimizing Therapies Using Therapeutic Drug Monitoring: Current Strategies and Future Perspectives
Peter M. Irving, K Gecse
Gastroenterology (2022) Vol. 162, Iss. 5, pp. 1512-1524
Open Access | Times Cited: 73

Showing 1-25 of 73 citing articles:

Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study
Neil Chanchlani, Simeng Lin, Claire Bewshea, et al.
˜The œLancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 6, pp. 521-538
Open Access | Times Cited: 33
Understanding the therapeutic toolkit for inflammatory bowel disease
Sophie Vieujean, Vipul Jairath, Laurent Peyrin‐Biroulet, et al.
Nature Reviews Gastroenterology & Hepatology (2025)
Closed Access | Times Cited: 2
Proactive Therapeutic Drug Monitoring Versus Conventional Management for Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis
Nghia Nguyen, Virginia Solitano, Sudheer K. Vuyyuru, et al.
Gastroenterology (2022) Vol. 163, Iss. 4, pp. 937-949.e2
Open Access | Times Cited: 45
Overview of therapeutic drug monitoring and clinical practice
Zijun Fang, He Zhang, Jiuchuan Guo, et al.
Talanta (2023) Vol. 266, pp. 124996-124996
Closed Access | Times Cited: 29
Bioadhesive Microcarriers Encapsulated with IL‐27 High Expressive MSC Extracellular Vesicles for Inflammatory Bowel Disease Treatment
Min Nie, Danqing Huang, Guopu Chen, et al.
Advanced Science (2023) Vol. 10, Iss. 32
Open Access | Times Cited: 22
Biosensing materials for monoclonal antibody detection: An overview
Yuxin Zhang, Fang Fan, Yifeng Chai, et al.
Deleted Journal (2024) Vol. 2, Iss. 2
Open Access | Times Cited: 7
Revolutionizing Precision Medicine: Exploring Wearable Sensors for Therapeutic Drug Monitoring and Personalized Therapy
Yuqiao Liu, Junmin Li, Shenghao Xiao, et al.
Biosensors (2023) Vol. 13, Iss. 7, pp. 726-726
Open Access | Times Cited: 19
Exploring human biology with N-of-1 clinical trials
Nicholas J. Schork, Brett K. Beaulieu‐Jones, Winnie S. Liang, et al.
Cambridge Prisms Precision Medicine (2023) Vol. 1
Open Access | Times Cited: 16
Exosomal miR-103a-3p from Crohn’s Creeping Fat-Derived Adipose-Derived Stem Cells Contributes to Intestinal Fibrosis by Targeting TGFBR3 and Activating Fibroblasts
Wenwei Qian, Yihan Xu, Weiwei Wen, et al.
Journal of Crohn s and Colitis (2023) Vol. 17, Iss. 8, pp. 1291-1308
Closed Access | Times Cited: 15
Systematic Review and Meta-analysis: The Association Between Serum Ustekinumab Trough Concentrations and Treatment Response in Inflammatory Bowel Disease
Abhinav Vasudevan, Vivek Tharayil, Laura H. Raffals, et al.
Inflammatory Bowel Diseases (2023) Vol. 30, Iss. 4, pp. 660-670
Open Access | Times Cited: 15
Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology
Dahham Alsoud, Dirk Jan A. R. Moes, Zhigang Wang, et al.
Therapeutic Drug Monitoring (2024) Vol. 46, Iss. 3, pp. 291-308
Closed Access | Times Cited: 5
Anti-tumor Necrosis Factor Drug Concentration Is Not Associated with Disease Outcomes in Pouchitis: A Retrospective, International Study
Sailish Honap, Bénédicte Caron, Jacob E. Ollech, et al.
Digestive Diseases and Sciences (2025)
Closed Access
Evolving Effective Drug Therapies with Multi-objective Genetic Algorithm
Tiancong Zhang, Shaowei Weng, Shu‐Chuan Chu, et al.
Lecture notes in electrical engineering (2025), pp. 277-288
Closed Access
Individualized antibiotic dosage regimens for patients with augmented renal clearance
Axi Shi, Qiang Qu, Hai-Hui Zhuang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 15
Comparative effectiveness of ustekinumab vs. vedolizumab for anti-TNF-naïve or anti-TNF-exposed Crohn's disease: a multicenter cohort study
Hongsheng Yang, Zhaopeng Huang, Miao Li, et al.
EClinicalMedicine (2023) Vol. 66, pp. 102337-102337
Open Access | Times Cited: 13
Therapeutic Drug Monitoring of Infliximab in Acute Severe Ulcerative Colitis
Benjamin L. Gordon, Robert Battat
Journal of Clinical Medicine (2023) Vol. 12, Iss. 10, pp. 3378-3378
Open Access | Times Cited: 10
White Paper: American Gastroenterological Association Position Statement: The Future of IBD Care in the United States–Removing Barriers and Embracing Opportunities
M. Anthony Sofia, Joseph D. Feuerstein, Leslie Narramore, et al.
Clinical Gastroenterology and Hepatology (2024) Vol. 22, Iss. 5, pp. 944-955
Open Access | Times Cited: 3
Greenness assessment of microextraction techniques in therapeutic drug monitoring
Parastoo Hosseini Pour, Foad Mashayekhi, Seyed Mosayeb Daryanavard
Bioanalysis (2024) Vol. 16, Iss. 8, pp. 249-278
Closed Access | Times Cited: 3
Real world population pharmacokinetic study in children and young adults with inflammatory bowel disease discovers novel blood and stool microbial predictors of vedolizumab clearance
Ruben J. Colman, Tomoyuki Mizuno, Keizo Fukushima, et al.
Alimentary Pharmacology & Therapeutics (2022) Vol. 57, Iss. 5, pp. 524-539
Open Access | Times Cited: 16
A novel AD theranostic platform with NIR-II laser controlled drug release and real-time monitoring of therapeutic outcomes
Zhili Qiu, Guojun Cao, Shanrong Lv, et al.
Chemical Engineering Journal (2023) Vol. 469, pp. 143882-143882
Closed Access | Times Cited: 9
Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases
Ingrid Jyssum, Johanna Elin Gehin, Joseph Sexton, et al.
Lara D. Veeken (2023) Vol. 63, Iss. 6, pp. 1746-1755
Open Access | Times Cited: 9
Therapeutic drug monitoring in inflammatory bowel disease: A practical approach
Devendra Desai
Indian Journal of Gastroenterology (2024) Vol. 43, Iss. 1, pp. 93-102
Closed Access | Times Cited: 2
Mesenteric adipose-derived exosomal TINAGL1 enhances intestinal fibrosis in Crohn's Disease via SMAD4
Yidong Chen, Junrong Li, Xiao‐Peng Zhang, et al.
Journal of Advanced Research (2024)
Open Access | Times Cited: 2
Pharmacokinetics of S1P receptor modulators in the treatment of ulcerative colitis
Sophie Vieujean, Laurent Peyrin-Biroulet
Expert Opinion on Drug Metabolism & Toxicology (2024) Vol. 20, Iss. 9, pp. 881-892
Closed Access | Times Cited: 2
3D Printing of Dietary Products for the Management of Inborn Errors of Intermediary Metabolism in Pediatric Populations
Paola Carou‐Senra, Lucía Rodríguez‐Pombo, Einés Monteagudo-Vilavedra, et al.
Nutrients (2023) Vol. 16, Iss. 1, pp. 61-61
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top